<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764344</url>
  </required_header>
  <id_info>
    <org_study_id>WMed-2020-0690</org_study_id>
    <nct_id>NCT04764344</nct_id>
  </id_info>
  <brief_title>Haloperidol for the Treatment of Nausea and Vomiting in the ED</brief_title>
  <official_title>A Single Center, Randomized Controlled Prospective Double-blinded Trial Comparing Haloperidol to Standard Ondansetron Therapy for Control of Nausea and Vomiting in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Michigan University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Michigan University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, double-blind, randomized, controlled trial in patients who present to the&#xD;
      emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300&#xD;
      patients age 18-55 presenting to the emergency department with chief complaint of nausea or&#xD;
      vomiting will be enrolled from February 2021 - February 2022. Patients will be randomized and&#xD;
      symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by&#xD;
      telephone at 24 hours.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a single-center prospective randomized double-blinded non-inferiority trial with potential assessment of superiority comparing haloperidol to ondansetron for the treatment of nausea and vomiting.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Treatment allocations will be revealed only after study completion, unless there is concern for a serious adverse event in which case treatment team and patient will be unblinded. Interim analysis will be performed at 150 participants to evaluate for effectiveness and power</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>from enrollment to 30, 60, and 90 minutes after drug administration</time_frame>
    <description>Mean change in visual analog scale (VAS) of self-rated nausea severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesia</measure>
    <time_frame>0, 30, 60, 90 minutes</time_frame>
    <description>Measurement of analgesia graded based on a self-reported validated 10 point visual analog scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in marijuana users</measure>
    <time_frame>Baseline (time 0)</time_frame>
    <description>Marijuanna use will be documented and quantified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QT prolongation</measure>
    <time_frame>Baseline (time 0) and 90 minutes</time_frame>
    <description>QT will be measured on the cardiac monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of side-effects</measure>
    <time_frame>0, 30, 60, 90 minutes and 24 hours</time_frame>
    <description>Inquiry about side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Vomiting</condition>
  <condition>Nausea</condition>
  <condition>Abdominal Pain</condition>
  <condition>Cannabis Use</condition>
  <arm_group>
    <arm_group_label>Haloperidol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg of IV haloperidol diluted to a final concentration of 5 mL with 0.9% sodium chloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg of IV ondansetron diluted to a final concentration of 5 mL with 0.9% sodium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP</description>
    <arm_group_label>Haloperidol</arm_group_label>
    <other_name>Haldol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Ondansetron</description>
    <arm_group_label>Ondansetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  presenting to the emergency department with chief complaint of nausea or vomiting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  abnormal blood pressure (&gt;200/100mmHg or &lt;90/40mmHg),&#xD;
&#xD;
          -  fever (&gt;100.4F),&#xD;
&#xD;
          -  acute trauma,&#xD;
&#xD;
          -  QT &gt; 450ms on cardiac monitor,&#xD;
&#xD;
          -  altered mental status (GCS &lt; 15),&#xD;
&#xD;
          -  chest pain,&#xD;
&#xD;
          -  known allergy to haloperidol or ondansetron,&#xD;
&#xD;
          -  Parkinson's disease,&#xD;
&#xD;
          -  pregnancy or lactation,&#xD;
&#xD;
          -  use of any antiemetic in the previous 8 hours,&#xD;
&#xD;
          -  nausea and vomiting associated with vertigo,&#xD;
&#xD;
          -  prisoners or any wards of the state.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica McCoy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Michigan University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica McCoy, MD</last_name>
    <phone>2693376600</phone>
    <email>jessica.mccoy@med.wmich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brenton Kinker, MD</last_name>
    <phone>2693376600</phone>
    <email>brenton.kinker@med.wmich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jessica McCoy, MD</last_name>
      <phone>269-337-6600</phone>
      <email>jessica.mccoy@med.wmich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Ferris, RN</last_name>
      <phone>2693416662</phone>
      <email>ferrisp@bronsonhg.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western Michigan University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jessica McCoy</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 4, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT04764344/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

